Section Arrow
ENTA.NASDAQ
- Enanta Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/16 04:41 EST
Regular Hours
Last
 12.06
+0.34 (+2.90%)
Day High 
12.5 
Prev. Close
11.72 
1-M High
12.47 
Volume 
276.15K 
Bid
11.4
Ask
12.06
Day Low
11.7 
Open
11.98 
1-M Low
10.2 
Market Cap 
338.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.25 
20-SMA 10.99 
50-SMA 10.16 
52-W High 15.34 
52-W Low 4.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.32/-3.27
Enterprise Value
392.10M
Balance Sheet
Book Value Per Share
2.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
67.64M
Operating Revenue Per Share
2.79
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 04:41 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.